RegulatoryJun 9, 2026, 09:21 AM
Longeveron Granted EMA SME Status, Accelerating Drug Development
AI Summary
Longeveron Inc. announced it has been granted Small or Medium-sized Enterprise (SME) status by the European Medicines Agency (EMA). This designation provides significant benefits, including scientific advice, protocol assistance, and reduced administrative fees, aiming to accelerate drug development and patient access to treatments. The EMA's SME program has historically shown improved success rates for regulatory approvals, with SME marketing authorization applications reaching an 89% success rate in 2020.
Key Highlights
- Longeveron granted Small or Medium-sized Enterprise (SME) status by the European Medicines Agency (EMA).
- SME status provides scientific advice, protocol assistance, and dedicated EMA personnel support.
- Allows early dialogue with EMA to discuss regulatory strategy, aiming to mitigate delays.
- Offers reduced administrative fees throughout the drug development process.
- EMA data shows SME marketing authorization success rate reached 89% in 2020.
- Over 40% of medicines selected for EMA's PRIME scheme were from SMEs.
- SMEs developed nearly 20% of all human medicines authorized in 2020, half for rare diseases.
Price Impact
More from LGVN